

CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

<i>THOUSANDS OF \$ (except per share data)</i>	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Revenues	27,433	23,317	78,330	65,310
Cost of sales (exclusive of amortization of intangible assets)	(9,558)	(9,042)	(27,384)	(25,686)
Gross Profit	17,875	14,275	50,946	39,624
Research and development expenses	(2,007)	(2,697)	(7,073)	(7,764)
Selling and marketing expenses	(10,588)	(10,619)	(30,331)	(31,280)
General and administrative expenses	(7,459)	(5,735)	(19,536)	(16,936)
Amortization of intangible assets	(1,297)	(1,327)	(3,939)	(3,575)
Other operating income (expense), net	834	11	787	(183)
Operating loss	(2,642)	(6,092)	(9,146)	(20,114)
Financial income	502	197	1,375	1,772
Financial expense	(5,876)	(4,960)	(17,105)	(12,552)
Loss before income tax	(8,016)	(10,855)	(24,876)	(30,894)
Income tax	6	(344)	285	(334)
Loss for the period	(8,010)	(11,189)	(24,591)	(31,228)
Loss per share attributable to parent				
Basic and diluted	(0.16)	(0.40)	(0.50)	(1.14)

CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

<i>THOUSANDS OF \$</i>	as of September 30, 2025	as of December 31, 2024
ASSETS		
Goodwill	37,054	35,926
Intangible assets	41,301	40,592
Property, plant and equipment	5,426	4,363
Right-of-use assets	11,334	8,617
Financial assets	944	936
Non-current assets	96,059	90,434
Inventories	6,082	3,869
Trade receivables	18,237	14,440
Prepaid expenses and other current assets	1,887	1,788
Cash and cash equivalents	32,014	46,798
Current assets	58,220	66,895
Total assets	154,279	157,329
EQUITY		
Share capital	214,670	214,670
Issuance premium	153,177	153,177
Accumulated deficit	(394,106)	(369,515)
Share-based compensation	18,642	17,124
Translation reserve	(646)	(615)
Total equity	(8,263)	14,841
LIABILITIES		
Loans and borrowings	75,920	50,967
Lease liabilities	10,024	7,413
Other non-current financial liabilities	25,438	41,445
Non-current liabilities	111,382	99,825
Loans and borrowings	-	324
Lease liabilities	1,961	1,360
Trade payables	9,389	8,001
Other current liabilities	7,237	6,567
Other current financial liabilities	32,573	26,411
Current liabilities	51,160	42,663
Total liabilities	162,542	142,488
Total equity and liabilities	154,279	157,329

CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS

	Nine Months Ended September 30,	
<i>THOUSANDS OF \$</i>	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES		
Operating loss	(9,146)	(20,114)
Depreciation	2,828	2,271
Amortization of intangible assets	3,939	3,575
Provision for inventory obsolescence	794	-
Share-based compensation	1,518	1,059
Other non-cash transactions	(853)	(85)
Cash used in operations before working capital changes	(920)	(13,294)
Changes in operating assets and liabilities		
Increase (-) in inventories	(1,383)	(1,605)
Increase (-) in receivables	(538)	(3,536)
Increase (+) in payables	274	3,023
Net cash outflow from operating activities	(2,567)	(15,412)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(1,103)	(996)
Acquisition and generation of intangible assets	-	(971)
Cash from acquisition of Exosome Diagnostics	755	-
GPS earnout payment	(21,252)	-
Interest received	1,249	560
Net cash outflow from investing activities	(20,351)	(1,407)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from issuance of shares, net of transaction costs	-	37,206
Proceeds from loan obligation	24,250	53,051
GPS earnout payment – financing option	(6,719)	-
Repayment of loan obligation, loan modification, and debt extinguishment costs	(324)	(39,929)
Payment of lease liability	(1,570)	(1,409)
Payment of interest	(7,175)	(4,899)
Other financial expense	(344)	(306)
Net cash inflow from financing activities	8,118	43,714
Net (decrease) / increase in cash and cash equivalents	(14,800)	26,895
Cash and cash equivalents at beginning of the period	46,798	22,380
Effect of exchange rates	16	(3)